The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InGilead Sciences and Galapagos NV are in advanced negotiations to collaborate on a novel T Cell Engager program. The partnership aims to develop innovative therapies specifically targeting autoimmune diseases, strengthening both companies' positions in this vital sector. This strategic move follows Gilead's recent acquisition of Ouro Medicines, which provided the foundational assets for the program. Both companies seek to leverage their combined expertise to expand their pipelines in the high-growth immunology market. While the deal is in its final stages and not yet finalized, the market is closely watching for an official announcement. This collaboration is expected to drive innovation in T-cell technology and provide new therapeutic solutions for patients.